https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global clinical genomic data analysis market size was valued at USD 1.5 billion in 2023 and is projected to reach USD 6.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 17.2% during the forecast period. This market growth is driven by the increasing adoption of genomic sequencing technologies, advancements in bioinformatics, and the rising prevalence of chronic diseases that necessitate personalized medicine and targeted therapies.
A major growth factor for the clinical genomic data analysis market is the exponential increase in the volume of genomic data being generated. With the cost of sequencing dropping and the speed of sequencing increasing, more genomic data is being produced than ever before. This abundance of data requires sophisticated analysis tools and software to interpret and derive meaningful insights, driving the demand for advanced genomic data analysis solutions. Additionally, the integration of artificial intelligence and machine learning algorithms in genomics is further enhancing the capabilities of these analysis tools, enabling more accurate and faster data interpretation.
Another significant factor contributing to market growth is the rising incidence of genetic disorders and cancers, which necessitates comprehensive genomic analysis for accurate diagnosis and personalized treatment plans. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, relies heavily on the insights gained from genomic data analysis. As the understanding of the genetic basis of diseases deepens, the demand for clinical genomic data analysis is expected to surge, further propelling market growth.
The integration of NGS Informatics and Clinical Genomics is revolutionizing the field of personalized medicine. By leveraging next-generation sequencing (NGS) technologies, researchers and clinicians can now analyze vast amounts of genomic data with unprecedented speed and accuracy. This integration enables the identification of genetic variants that may contribute to disease, allowing for more precise diagnosis and the development of targeted therapies. As the capabilities of NGS technologies continue to expand, the role of informatics in managing and interpreting this data becomes increasingly critical. The seamless integration of NGS Informatics and Clinical Genomics is paving the way for more effective and personalized healthcare solutions, ultimately improving patient outcomes.
Government initiatives and funding in genomics research also play a crucial role in the expansion of the clinical genomic data analysis market. Many governments around the world are investing heavily in genomic research projects and infrastructure to advance medical research and improve public health outcomes. For instance, initiatives like the 100,000 Genomes Project in the UK and the All of Us Research Program in the US underscore the importance of genomics in understanding human health and disease, thereby boosting the demand for genomic data analysis tools and services.
Regional outlook reveals significant growth opportunities in emerging markets, particularly in the Asia Pacific region. Countries like China, India, and Japan are witnessing rapid advancements in healthcare infrastructure and increasing investments in genomics research. Additionally, favorable government policies and the presence of a large patient pool make this region a lucrative market for clinical genomic data analysis. North America continues to dominate the market due to high healthcare spending, advanced research facilities, and the early adoption of new technologies. Europe also shows steady growth with significant contributions from countries like the UK, Germany, and France.
The component segment of the clinical genomic data analysis market is divided into software and services. The software segment encompasses various bioinformatics tools and platforms used for genomic data analysis. These tools are essential for the effective management, storage, and interpretation of the massive amounts of genomic data generated. The growing complexity of genomic data necessitates the use of robust software solutions that can handle large datasets and provide accurate insights. As a result, the software segment is expected to witness significant growth during the forecast period.
The services segment includes
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
There are many initiatives attempting to harmonize data collection across human clinical studies using common data elements (CDEs). The increased use of CDEs in large prior studies can guide researchers planning new studies. For that purpose, we analyzed the All of Us (AoU) program, an ongoing US study intending to enroll one million participants and serve as a platform for numerous observational analyses. AoU adopted the OMOP Common Data Model to standardize both research (Case Report Form [CRF]) and real-world (imported from Electronic Health Records [EHRs]) data. AoU standardized specific data elements and values by including CDEs from terminologies such as LOINC and SNOMED CT. For this study, we defined all elements from established terminologies as CDEs and all custom concepts created in the Participant Provided Information (PPI) terminology as unique data elements (UDEs). We found 1 033 research elements, 4 592 element-value combinations and 932 distinct values. Most elements were UDEs (869, 84.1%), while most CDEs were from LOINC (103 elements, 10.0%) or SNOMED CT (60, 5.8%). Of the LOINC CDEs, 87 (53.1% of 164 CDEs) originated from previous data collection initiatives, such as PhenX (17 CDEs) and PROMIS (15 CDEs). On a CRF level, The Basics (12 of 21 elements, 57.1%) and Lifestyle (10 of 14, 71.4%) were the only CRFs with multiple CDEs. On a value level, 61.7% of distinct values are from an established terminology. AoU demonstrates the use of the OMOP model for integrating research and routine healthcare data (64 elements in both contexts), which allows for monitoring lifestyle and health changes outside the research setting. The increased inclusion of CDEs in large studies (like AoU) is important in facilitating the use of existing tools and improving the ease of understanding and analyzing the data collected, which is more challenging when using study specific formats.
This document, Innovating the Data Ecosystem: An Update of The Federal Big Data Research and Development Strategic Plan, updates the 2016 Federal Big Data Research and Development Strategic Plan. This plan updates the vision and strategies on the research and development needs for big data laid out in the 2016 Strategic Plan through the six strategies areas (enhance the reusability and integrity of data; enable innovative, user-driven data science; develop and enhance the robustness of the federated ecosystem; prioritize privacy, ethics, and security; develop necessary expertise and diverse talent; and enhance U.S. leadership in the international context) to enhance data value and reusability and responsiveness to federal policies on data sharing and management.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Total Business Enterprise R&D Personnel: Per Thousand Employment In Industry data was reported at 17.169 Per 1000 in 2020. This records an increase from the previous number of 15.152 Per 1000 for 2019. United States US: Total Business Enterprise R&D Personnel: Per Thousand Employment In Industry data is updated yearly, averaging 13.282 Per 1000 from Dec 2011 (Median) to 2020, with 10 observations. The data reached an all-time high of 17.169 Per 1000 in 2020 and a record low of 12.478 Per 1000 in 2012. United States US: Total Business Enterprise R&D Personnel: Per Thousand Employment In Industry data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s United States – Table US.OECD.MSTI: Number of Researchers and Personnel on Research and Development: OECD Member: Annual.
Definition of MSTI variables 'Value Added of Industry' and 'Industrial Employment':
R&D data are typically expressed as a percentage of GDP to allow cross-country comparisons. When compiling such indicators for the business enterprise sector, one may wish to exclude, from GDP measures, economic activities for which the Business R&D (BERD) is null or negligible by definition. By doing so, the adjusted denominator (GDP, or Value Added, excluding non-relevant industries) better correspond to the numerator (BERD) with which it is compared to.
The MSTI variable 'Value added in industry' is used to this end:
It is calculated as the total Gross Value Added (GVA) excluding 'real estate activities' (ISIC rev.4 68) where the 'imputed rent of owner-occupied dwellings', specific to the framework of the System of National Accounts, represents a significant share of total GVA and has no R&D counterpart. Moreover, the R&D performed by the community, social and personal services is mainly driven by R&D performers other than businesses.
Consequently, the following service industries are also excluded: ISIC rev.4 84 to 88 and 97 to 98. GVA data are presented at basic prices except for the People's Republic of China, Japan and New Zealand (expressed at producers' prices).In the same way, some indicators on R&D personnel in the business sector are expressed as a percentage of industrial employment. The latter corresponds to total employment excluding ISIC rev.4 68, 84 to 88 and 97 to 98.
https://www.ibisworld.com/about/termsofuse/https://www.ibisworld.com/about/termsofuse/
Clinical trial data management (CDM) providers have experienced robust growth in recent years, driven by several key factors. Two major catalysts contributing to this growth are an increasing demand for innovative therapies and treatments and the rising prevalence of chronic diseases worldwide. As pharmaceutical companies race to develop new drugs and biologics to address unmet medical needs, the volume and complexity of clinical trials have surged. A jump in clinical trial activity has fueled the need for efficient and reliable data management solutions to handle the vast amounts of data generated throughout the drug development process. At the same time, regulatory bodies in the US and internationally mounting scrutiny of clinical trial data integrity has prompted pharmaceutical companies to outsource data management to compliance and transparency. In all, revenue has been expanding at a CAGR of 5.9% to an estimated $8.9 billion over the past five years, including expected growth of 2.7% in 2024. One central trend behind clinical trial data management providers’ growth is the increasingly complex clinical trial landscape. Medical and tech advances have made the clinical trial process more intricate, expanding the volume and variety of data collected during clinical trials, introducing significant challenges for data management. Clinical trial data management companies have developed an increasingly vital role in addressing these challenges by providing specialized services. Outsourcing data management has been especially crucial for smaller biopharmaceutical companies that depend heavily on successful clinical trials but lack the capital or resources to invest in in-house capabilities. Outsourcing aspects of the research and development stage, including clinical trial data management, will become an increasingly attractive option for downstream pharmaceutical and medical device manufacturers, positioning the industry for growth. Competition between smaller or mid-sized pharma and the leading multinational manufacturers to bring novel therapies to market will strengthen CDM companies’ role. An approaching patent cliff will also drive demand for clinical trial data management services as revenue declines and heightened competition from generic drugs accelerate clinical trial activity and cost mitigation efforts. Revenue will continue growing, rising at a CAGR of 3.3% over the next five years, reaching an estimated $10.5 billion in 2029.
The RVCAT database contains data that have been collected on various vessel operations on the Great Lakes and select connecting waterways. This section of Reference Tables specifically handles repetitive or standardized information that is called upon in the main tables of the RVCAT database. Reference tables are used in database design in order to standardize often used values and to make the data file efficient. All of the terms defined in the reference tables have been determined by the United States Geological Survey, Great Lakes Science Center and it’s partners. Data Quality: Note that the following data release is a snapshot of the database at the time of release. Some data quality checks are still being undertaken after the time of release. Also, a large section of this database includes legacy data that if issues arise for cannot be addressed, but nevertheless adds great value to the database. When approaching the following data release, it is strongly suggested to approach the Great Lakes Science Center's researchers for input. Distribution Liability Statement: Unless otherwise stated, all data, metadata and related materials are considered to satisfy the quality standards relative to the purpose for which the data were collected. Although these data and associated metadata have been reviewed for accuracy and completeness and approved for release by the U.S. Geological Survey (USGS), no warranty expressed or implied is made regarding the display or utility of the data on any other system or for general or scientific purposes, nor shall the act of distribution constitute any such warranty.
In 2021, Gartner was the leading company in the market research and data analytics sector in the United States. Roughly ** million U.S. dollars separated the top two companies, as Nielsen generated a revenue of approximately *** billion U.S. dollars compared to the **** billion U.S. dollars generated by Gartner.
This archive publishes and preserves short and long-term research data collected from studies funded by:
Each archived data set (i.e., 'data publication') contains at least one data set, complete metadata for the data set(s), and any other documentation the researcher deemed important to understanding the data set(s). The data catalog entries present the metadata and a link to the data. In some cases the data link is to a different archive.
The Nationwide Emergency Department Sample (NEDS) was created to enable analyses of emergency department (ED) utilization patterns and support public health professionals, administrators, policymakers, and clinicians in their decision-making regarding this critical source of care. The NEDS can be weighted to produce national estimates. The NEDS is the largest all-payer ED database in the United States. It was constructed using records from both the HCUP State Emergency Department Databases (SEDD) and the State Inpatient Databases (SID), both also described in healthdata.gov. The SEDD capture information on ED visits that do not result in an admission (i.e., treat-and-release visits and transfers to another hospital). The SID contain information on patients initially seen in the emergency room and then admitted to the same hospital. The NEDS contains 25-30 million (unweighted) records for ED visits for over 950 hospitals and approximates a 20-percent stratified sample of U.S. hospital-based EDs. The NEDS contains information about geographic characteristics, hospital characteristics, patient characteristics, and the nature of visits (e.g., common reasons for ED visits, including injuries). The NEDS contains clinical and resource use information included in a typical discharge abstract, with safeguards to protect the privacy of individual patients, physicians, and hospitals (as required by data sources). It includes ED charge information for over 75% of patients, regardless of payer, including patients covered by Medicaid, private insurance, and the uninsured. The NEDS excludes data elements that could directly or indirectly identify individuals, hospitals, or states.
U.S. Government Workshttps://www.usa.gov/government-works
License information was derived automatically
The USDA Nematode Collection is one of the largest and most valuable nematode collections in existence. It contains over 49,000 permanent slides and vials, with a total repository of nematode specimens reaching several million, including Cobb-Steiner, Thorne, and other valuable collections. Nematodes contained in this collection originate from world-wide sources. The USDA Nematode Collection Database contains over 38,000 species entries. A broad range of data is stored for each specimen, including species, host, origin, collector, date collected and date received. All records are searchable and available to the public through the online database. The physical collection is housed at the USDA Nematology Laboratory in Beltsville, MD. Specimens are available for loan to scientists who cannot personally visit the collection. Please see the Policy for Loaning USDANC Specimens for more information on this process. Scientists and other workers are always welcomed and encouraged to deposit material into the collection. Resources in this dataset:Resource Title: USDA Nematode Collection Database. File Name: Web Page, url: https://nt.ars-grin.gov/nematodes/search.cfm The database portal for this collection
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Values correspond to mean (standard deviation) or N (%), All of Us Research Program, 2017–2019.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: Business-Financed BERD: % of Value Added data was reported at 3.606 % in 2021. This records a decrease from the previous number of 3.618 % for 2020. United States US: Business-Financed BERD: % of Value Added data is updated yearly, averaging 2.467 % from Dec 1981 (Median) to 2021, with 41 observations. The data reached an all-time high of 3.618 % in 2020 and a record low of 1.689 % in 1981. United States US: Business-Financed BERD: % of Value Added data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s United States – Table US.OECD.MSTI: Business Enterprise Investment on Research and Development: OECD Member: Annual.
All gillnet data represented here expand upon vessel operations (OP table) data, all of which are collected by the United States Geological Survey, Great Lakes Science Center and its partners. The Gillnet Tables contain data collected from the research vessel deploying various gear used for gillnet data collection. The database uses sample_type to indicate the gear deployed. The tables relating to Gillnet are: GN_Annulus.csv, GN_Catch.csv, GN_Effort.csv, GN_Fish.csv, GN_L, GN_LF.csv, GN_OP.csv, GN_Prey.csv, GN_Stomach.csv, LMMB_Fish_Prey.csv, and LMMB_Invert_Prey.csv Data Quality: Note that the following data release is a snapshot of the database at the time of release. Some data quality checks are still being undertaken after the time of release. Also, a large section of this database includes legacy data that if issues arrise for cannot be addressed, but nevertheless adds great value to the database. When approaching the following data release, it is strongly suggested to approach the Great Lakes Science Center's researchers for input. Distribution Liability Statement: Unless otherwise stated, all data, metadata and related materials are considered to satisfy the quality standards relative to the purpose for which the data were collected. Although these data and associated metadata have been reviewed for accuracy and completeness and approved for release by the U.S. Geological Survey (USGS), no warranty expressed or implied is made regarding the display or utility of the data on any other system or for general or scientific purposes, nor shall the act of distribution constitute any such warranty.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
United States US: BERD Performed: Service Industries data was reported at 44.294 % in 2021. This records an increase from the previous number of 42.320 % for 2020. United States US: BERD Performed: Service Industries data is updated yearly, averaging 29.608 % from Dec 1987 (Median) to 2021, with 35 observations. The data reached an all-time high of 44.294 % in 2021 and a record low of 8.223 % in 1987. United States US: BERD Performed: Service Industries data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s United States – Table US.OECD.MSTI: Business Enterprise Investment on Research and Development: OECD Member: Annual.
For the United States, from 2021 onwards, changes to the US BERD survey questionnaire allowed for more exhaustive identification of acquisition costs for ‘identifiable intangible assets’ used for R&D. This has resulted in a substantial increase in reported R&D capital expenditure within BERD. In the business sector, the funds from the rest of the world previously included in the business-financed BERD, are available separately from 2008. From 2006 onwards, GOVERD includes state government intramural performance (most of which being financed by the federal government and state government own funds). From 2016 onwards, PNPERD data are based on a new R&D performer survey. In the higher education sector all fields of SSH are included from 2003 onwards.
Following a survey of federally-funded research and development centers (FFRDCs) in 2005, it was concluded that FFRDC R&D belongs in the government sector - rather than the sector of the FFRDC administrator, as had been reported in the past. R&D expenditures by FFRDCs were reclassified from the other three R&D performing sectors to the Government sector; previously published data were revised accordingly. Between 2003 and 2004, the method used to classify data by industry has been revised. This particularly affects the ISIC category “wholesale trade” and consequently the BERD for total services.
U.S. R&D data are generally comparable, but there are some areas of underestimation:
Breakdown by type of R&D (basic research, applied research, etc.) was also revised back to 1998 in the business enterprise and higher education sectors due to improved estimation procedures.
The methodology for estimating researchers was changed as of 1985. In the Government, Higher Education and PNP sectors the data since then refer to employed doctoral scientists and engineers who report their primary work activity as research, development or the management of R&D, plus, for the Higher Education sector, the number of full-time equivalent graduate students with research assistantships averaging an estimated 50 % of their time engaged in R&D activities. As of 1985 researchers in the Government sector exclude military personnel. As of 1987, Higher education R&D personnel also include those who report their primary work activity as design.
Due to lack of official data for the different employment sectors, the total researchers figure is an OECD estimate up to 2019. Comprehensive reporting of R&D personnel statistics by the United States has resumed with records available since 2020, reflecting the addition of official figures for the number of researchers and total R&D personnel for the higher education sector and the Private non-profit sector; as well as the number of researchers for the government sector. The new data revise downwards previous OECD estimates as the OECD extrapolation methods drawing on historical US data, required to produce a consistent OECD aggregate, appear to have previously overestimated the growth in the number of researchers in the higher education sector.
Pre-production development is excluded from Defence GBARD (in accordance with the Frascati Manual) as of 2000. 2009 GBARD data also includes the one time incremental R&D funding legislated in the American Recovery and Reinvestment Act of 2009. Beginning with the 2000 GBARD data, budgets for capital expenditure – “R&D plant” in national terminology - are included. GBARD data for earlier years relate to budgets for current costs only.
By US Open Data Portal, data.gov [source]
This dataset contains over 300 examples of health IT policy levers used by states to advance interoperability, promote health IT and support delivery system reform. The U.S Government's Office of National Coordinator for Health Information Technology (ONC) has curated this catalog as part of its Health IT State Policy Levers Compendium. It provides an exhaustive directory on the policy levers being utilized, along with information on the state enacting them and their official sources. This collection seeks to act as a comprehensive guide for government officials and healthcare providers who are interested in state-based initiatives for optimizing health information technology. Explore the strategies your own state might be using to unlock improved patient outcomes!
For more datasets, click here.
- 🚨 Your notebook can be here! 🚨!
This dataset provides information on policy levers used by various states in the United States to promote health IT and advance interoperability. The comprehensive list includes over 300 documented examples of health IT policy levers used by these states. This catalog can be used to identify which specific policy levers are being used, as well as what activities they are associated with.
If you're interested in learning more about how states use health IT policy levers, this dataset is a great resource. It contains detailed information on each entry, including the state where it's being used, the status of that activity, a description of the activity and its purpose, and an official source for additional information about that particular entry.
Using this data set is easy - simply search for specific states or find out which kinds of activities each state is using their health IT policy levers for. You can also look up any specific application or implementation detail from each record by opening up its corresponding source URL link . With all this information at hand you can better understand how states use their health IT tools to make a difference in advancing interoperability within healthcare systems today!
- It can be used to provide states with potential models of successful health IT policy levers, allowing them to learn from the experiences of other states in developing and implementing health IT legislation.
- The dataset can also be used by researchers looking to study the effectiveness of existing health care policy levers, as well as to identify any gaps that need to be filled in order for certain policies to have a greater overall impact.
- Additionally, it could be used by industry stakeholders such as hospitals or other healthcare organizations for benchmarking their own efforts related to IT implementation, such as understanding what activities are being undertaken and which sources are being used for best practices or additional resources when making decisions related to new technology implementations into an organization's operations and services
If you use this dataset in your research, please credit the original authors. Data Source
Unknown License - Please check the dataset description for more information.
File: policy-levers-activities-catalog-csv-1.csv | Column name | Description | |:-------------------------|:----------------------------------------------------------------------------------------------| | state | The state in which the policy lever is being used. (String) | | policy_lever | Type of policy lever being used. (String) | | activity_status | Status of activity (e.g., active or inactive). (String) | | activity_description | Description of activity. (String) | | source | Source from where data is gathered from. (String) | | source_url | A link that points directly back to an original sources with additional information. (String) |
If you use this dataset in your research, please credit the original authors. If you use this dataset in your research, please credit US Open Data Portal, data.gov.
What We Eat in America (WWEIA) is the dietary intake interview component of the National Health and Nutrition Examination Survey (NHANES). WWEIA is conducted as a partnership between the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Services (DHHS). Two days of 24-hour dietary recall data are collected through an initial in-person interview, and a second interview conducted over the telephone within three to 10 days. Participants are given three-dimensional models (measuring cups and spoons, a ruler, and two household spoons) and/or USDA's Food Model Booklet (containing drawings of various sizes of glasses, mugs, bowls, mounds, circles, and other measures) to estimate food amounts. WWEIA data are collected using USDA's dietary data collection instrument, the Automated Multiple-Pass Method (AMPM). The AMPM is a fully computerized method for collecting 24-hour dietary recalls either in-person or by telephone. For each 2-year data release cycle, the following dietary intake data files are available: Individual Foods File - Contains one record per food for each survey participant. Foods are identified by USDA food codes. Each record contains information about when and where the food was consumed, whether the food was eaten in combination with other foods, amount eaten, and amounts of nutrients provided by the food. Total Nutrient Intakes File - Contains one record per day for each survey participant. Each record contains daily totals of food energy and nutrient intakes, daily intake of water, intake day of week, total number foods reported, and whether intake was usual, much more than usual or much less than usual. The Day 1 file also includes salt use in cooking and at the table; whether on a diet to lose weight or for other health-related reason and type of diet; and frequency of fish and shellfish consumption (examinees one year or older, Day 1 file only). DHHS is responsible for the sample design and data collection, and USDA is responsible for the survey’s dietary data collection methodology, maintenance of the databases used to code and process the data, and data review and processing. USDA also funds the collection and processing of Day 2 dietary intake data, which are used to develop variance estimates and calculate usual nutrient intakes. Resources in this dataset:Resource Title: What We Eat In America (WWEIA) main web page. File Name: Web Page, url: https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/wweianhanes-overview/ Contains data tables, research articles, documentation data sets and more information about the WWEIA program. (Link updated 05/13/2020)
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Context
The dataset tabulates the Brownstown population distribution across 18 age groups. It lists the population in each age group along with the percentage population relative of the total population for Brownstown. The dataset can be utilized to understand the population distribution of Brownstown by age. For example, using this dataset, we can identify the largest age group in Brownstown.
Key observations
The largest age group in Brownstown, IN was for the group of age 70-74 years with a population of 384 (12.77%), according to the 2021 American Community Survey. At the same time, the smallest age group in Brownstown, IN was the 80-84 years with a population of 82 (2.73%). Source: U.S. Census Bureau American Community Survey (ACS) 2017-2021 5-Year Estimates.
When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2017-2021 5-Year Estimates.
Age groups:
Variables / Data Columns
Good to know
Margin of Error
Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.
Custom data
If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.
Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.
This dataset is a part of the main dataset for Brownstown Population by Age. You can refer the same here
R&D Database provides Vehicle Crash Test data, Biomechanics Test Data, and Component Test Data to support NHTSA's motor vehicle and traffic safety goals.
The Digital Data Series encompasses a broad range of digital data, including computer programs, interpreted results of investigations, comprehensive reviewed data bases, spatial data sets, digital images and animation, and multimedia presentations that are not intended for printed release. Scientific reports in this series cover a wide variety of subjects on all facets of U.S. Geological Survey investigations and research that are of lasting scientific interest and value. Releases in the Digital Data Series offer access to scientific information that is available in digital form; the information is primarily for viewing, processing, and (or) analyzing by comput
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
This dataset covers all publically listed companies in the United States from 2000 to 2018, which are listed in the S&P index. The starting point of 2000 is due to the minimal data available in the BoardEX database before this time in relation to board directors' information. Compustat is the source of financial data. As previous research indicates, financial and utilities firms are excluded from the sample due to their distinct regulations, which expose their directors to liability risks that non-financial firms are not subject to (Adams and Mehran, 2012; Sila et al., 2016). The sample size of non-financial firms amounts to 17,220. Financial variable outliers are adjusted to the 98% level in accordance with Bharath and Shumway's (2008) study.
https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The global clinical genomic data analysis market size was valued at USD 1.5 billion in 2023 and is projected to reach USD 6.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 17.2% during the forecast period. This market growth is driven by the increasing adoption of genomic sequencing technologies, advancements in bioinformatics, and the rising prevalence of chronic diseases that necessitate personalized medicine and targeted therapies.
A major growth factor for the clinical genomic data analysis market is the exponential increase in the volume of genomic data being generated. With the cost of sequencing dropping and the speed of sequencing increasing, more genomic data is being produced than ever before. This abundance of data requires sophisticated analysis tools and software to interpret and derive meaningful insights, driving the demand for advanced genomic data analysis solutions. Additionally, the integration of artificial intelligence and machine learning algorithms in genomics is further enhancing the capabilities of these analysis tools, enabling more accurate and faster data interpretation.
Another significant factor contributing to market growth is the rising incidence of genetic disorders and cancers, which necessitates comprehensive genomic analysis for accurate diagnosis and personalized treatment plans. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, relies heavily on the insights gained from genomic data analysis. As the understanding of the genetic basis of diseases deepens, the demand for clinical genomic data analysis is expected to surge, further propelling market growth.
The integration of NGS Informatics and Clinical Genomics is revolutionizing the field of personalized medicine. By leveraging next-generation sequencing (NGS) technologies, researchers and clinicians can now analyze vast amounts of genomic data with unprecedented speed and accuracy. This integration enables the identification of genetic variants that may contribute to disease, allowing for more precise diagnosis and the development of targeted therapies. As the capabilities of NGS technologies continue to expand, the role of informatics in managing and interpreting this data becomes increasingly critical. The seamless integration of NGS Informatics and Clinical Genomics is paving the way for more effective and personalized healthcare solutions, ultimately improving patient outcomes.
Government initiatives and funding in genomics research also play a crucial role in the expansion of the clinical genomic data analysis market. Many governments around the world are investing heavily in genomic research projects and infrastructure to advance medical research and improve public health outcomes. For instance, initiatives like the 100,000 Genomes Project in the UK and the All of Us Research Program in the US underscore the importance of genomics in understanding human health and disease, thereby boosting the demand for genomic data analysis tools and services.
Regional outlook reveals significant growth opportunities in emerging markets, particularly in the Asia Pacific region. Countries like China, India, and Japan are witnessing rapid advancements in healthcare infrastructure and increasing investments in genomics research. Additionally, favorable government policies and the presence of a large patient pool make this region a lucrative market for clinical genomic data analysis. North America continues to dominate the market due to high healthcare spending, advanced research facilities, and the early adoption of new technologies. Europe also shows steady growth with significant contributions from countries like the UK, Germany, and France.
The component segment of the clinical genomic data analysis market is divided into software and services. The software segment encompasses various bioinformatics tools and platforms used for genomic data analysis. These tools are essential for the effective management, storage, and interpretation of the massive amounts of genomic data generated. The growing complexity of genomic data necessitates the use of robust software solutions that can handle large datasets and provide accurate insights. As a result, the software segment is expected to witness significant growth during the forecast period.
The services segment includes